• Users Online: 1401
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 29  |  Issue : 1  |  Page : 9-13

Update on hydroxychloroquine retinopathy

1 Little Flower Hospital and Research Center, Ernakulam, Kerala, India
2 Vitreo-Retina Services, L. V. Prasad Eye Institute, Hyderabad, Telangana, India
3 Vitreo-Retina Services, Aravind Eye Institute, Madurai, Tamil Nadu, India

Correspondence Address:
Remya Mareen Paulose
Little Flower Hospital and Research Center, Angamaly, Ernakulam, Kerala
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/kjo.kjo_29_17

Rights and Permissions

Hydroxychloroquine (HCQ) in recent times has been used in treatment for a variety of autoimmune diseases and dermatological and rheumatological conditions. Retinal toxicity from HCQ and its analog chloroquine has been recognized for many years. Retinal toxicity secondary to HCQ is irreversible and can continue to progress even after cessation of therapy. Prompt screening and serial monitoring, with the utilization of imaging modalities, is of paramount importance to early detection.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded774    
    Comments [Add]    

Recommend this journal